JP6867302B2 - タンパク質の特徴を改善する方法 - Google Patents

タンパク質の特徴を改善する方法 Download PDF

Info

Publication number
JP6867302B2
JP6867302B2 JP2017556995A JP2017556995A JP6867302B2 JP 6867302 B2 JP6867302 B2 JP 6867302B2 JP 2017556995 A JP2017556995 A JP 2017556995A JP 2017556995 A JP2017556995 A JP 2017556995A JP 6867302 B2 JP6867302 B2 JP 6867302B2
Authority
JP
Japan
Prior art keywords
protein
library
binding
candidate
display system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017556995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018517899A (ja
Inventor
ロバート ビー. デュブリッジ,
ロバート ビー. デュブリッジ,
Original Assignee
フル スペクトラム ジェネティクス, インコーポレイテッド
フル スペクトラム ジェネティクス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フル スペクトラム ジェネティクス, インコーポレイテッド, フル スペクトラム ジェネティクス, インコーポレイテッド filed Critical フル スペクトラム ジェネティクス, インコーポレイテッド
Publication of JP2018517899A publication Critical patent/JP2018517899A/ja
Application granted granted Critical
Publication of JP6867302B2 publication Critical patent/JP6867302B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B10/00—Directed molecular evolution of macromolecules, e.g. RNA, DNA or proteins
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Ecology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2017556995A 2015-05-21 2016-05-16 タンパク質の特徴を改善する方法 Active JP6867302B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562165173P 2015-05-21 2015-05-21
US62/165,173 2015-05-21
PCT/US2016/032660 WO2016187101A2 (en) 2015-05-21 2016-05-16 Method of improving characteristics of proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021001276A Division JP7109605B2 (ja) 2015-05-21 2021-01-07 タンパク質の特徴を改善する方法

Publications (2)

Publication Number Publication Date
JP2018517899A JP2018517899A (ja) 2018-07-05
JP6867302B2 true JP6867302B2 (ja) 2021-04-28

Family

ID=57320465

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017556995A Active JP6867302B2 (ja) 2015-05-21 2016-05-16 タンパク質の特徴を改善する方法
JP2021001276A Active JP7109605B2 (ja) 2015-05-21 2021-01-07 タンパク質の特徴を改善する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021001276A Active JP7109605B2 (ja) 2015-05-21 2021-01-07 タンパク質の特徴を改善する方法

Country Status (5)

Country Link
US (2) US10526597B2 (cg-RX-API-DMAC7.html)
EP (1) EP3297661B1 (cg-RX-API-DMAC7.html)
JP (2) JP6867302B2 (cg-RX-API-DMAC7.html)
ES (1) ES2881683T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016187101A2 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
EP3297661B1 (en) 2015-05-21 2021-06-30 Full Spectrum Genetics, Inc. Method of improving characteristics of proteins
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
JP7215997B2 (ja) 2016-11-23 2023-01-31 ハープーン セラピューティクス,インク. 前立腺特異的膜抗原(psma)を標的とする三重特異性タンパク質と使用方法
KR102275008B1 (ko) 2016-11-23 2021-07-13 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
SG10202107880XA (en) 2017-05-12 2021-09-29 Harpoon Therapeutics Inc Mesothelin binding proteins
US10730954B2 (en) 2017-05-12 2020-08-04 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
CA3078969A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
MX2020012217A (es) 2018-05-14 2021-03-02 Harpoon Therapeutics Inc Porción de unión para activación condicional de moléculas de inmunoglobulina.
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN119306844A (zh) 2018-09-25 2025-01-14 哈普恩治疗公司 Dll3结合蛋白及使用方法
WO2020232303A1 (en) 2019-05-14 2020-11-19 Harpoon Therapeutics, Inc. EpCAM BINDING PROTEINS AND METHODS OF USE
BR112022016550A2 (pt) 2020-02-21 2022-11-16 Harpoon Therapeutics Inc Proteínas de ligação a flt3 e métodos de uso

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2079802C (en) 1990-04-05 2001-09-18 Roberto Crea Walk-through mutagenesis
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6117679A (en) * 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
AU1456101A (en) 1999-11-03 2001-05-14 Maxygen, Inc. Antibody diversity generation
DE60224720D1 (en) * 2001-11-22 2008-03-06 Univ Keio Re
EP1660186B1 (en) 2003-08-18 2013-12-25 MedImmune, LLC Humanization of antibodies
US20060228350A1 (en) 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
US20060160178A1 (en) * 2003-11-17 2006-07-20 Jonathan Rothberg Methods of generating antibody diversity in vitro
ATE528396T1 (de) 2004-07-06 2011-10-15 Bioren Inc Look-through-mutagenese zur entwicklung veränderter polypeptide mit verbesserten eigenschaften
US8633139B2 (en) 2007-12-21 2014-01-21 Abbvie Biotherapeutics Inc. Methods of screening complex protein libraries to identify altered properties
US20120077691A1 (en) * 2010-09-24 2012-03-29 Full Spectrum Genetics, Inc. Method of analyzing binding interactions
JP5920835B2 (ja) * 2010-12-01 2016-05-18 田辺三菱製薬株式会社 無細胞翻訳系でFabを提示しうるポリヌクレオチド構築物ならびにそれを用いたFabの製造方法およびスクリーニング方法
US20120258866A1 (en) 2011-04-05 2012-10-11 Full Spectrum Genetics, Inc. Multi-dimensional selection of protein mutants using high throughput sequence analysis
US10947305B2 (en) 2015-03-20 2021-03-16 Full Spectrum Genetics, Inc. Anti-TNFα binding compounds and uses thereof
EP3297661B1 (en) 2015-05-21 2021-06-30 Full Spectrum Genetics, Inc. Method of improving characteristics of proteins

Also Published As

Publication number Publication date
WO2016187101A2 (en) 2016-11-24
JP7109605B2 (ja) 2022-07-29
US10526597B2 (en) 2020-01-07
JP2018517899A (ja) 2018-07-05
EP3297661A4 (en) 2018-11-21
US20190078081A1 (en) 2019-03-14
US20200123530A1 (en) 2020-04-23
WO2016187101A3 (en) 2017-04-20
EP3297661A2 (en) 2018-03-28
JP2021061852A (ja) 2021-04-22
ES2881683T3 (es) 2021-11-30
US11332735B2 (en) 2022-05-17
EP3297661B1 (en) 2021-06-30

Similar Documents

Publication Publication Date Title
JP7109605B2 (ja) タンパク質の特徴を改善する方法
KR102290949B1 (ko) 신규 항체 라이브러리 제조방법 및 이로부터 제조된 라이브러리
US20240044047A1 (en) Radically diverse human antibody library
JP7291700B2 (ja) mRNAディスプレイ抗体ライブラリー及び方法
EP3223014B1 (en) Method of analyzing binding interactions
US8178320B2 (en) Artificial antibody library with super-repertory
KR102194203B1 (ko) 항체 나이브 라이브러리의 생성 방법, 상기 라이브러리 및 그 적용(들)
KR102216032B1 (ko) 합성 항체 라이브러리의 생성 방법, 상기 라이브러리 및 그 적용(들)
EP4479583A1 (en) Single domain antibody libraries with maximized antibody developability characteristics
JP7337850B2 (ja) 抗体ライブラリー及びこれを用いた抗体スクリーニング方法
KR20230128290A (ko) 가변 중쇄 전용 라이브러리, 이의 제조 방법, 및 이의용도
Tiller Synthetic Antibodies
US20140235483A1 (en) Parallel determination of competitive binding and target specificity of a binding compound library by high-throughput dna sequencing

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190320

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210107

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210406

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210408

R150 Certificate of patent or registration of utility model

Ref document number: 6867302

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250